← All trials
NCT00399919
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2006
- Primary completion
- Mar 1, 2008
- Completion date
- Mar 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 69
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Leadiant Biosciences, Inc.Lead sponsor
- University of RochesterOverall official - principal investigator
- University of MassachusettsOverall official - principal investigator
- Western Suburban Cardiologists, Ltd.Overall official - principal investigator
- Baptist Clinical ResearchOverall official - principal investigator
- Asheville Cardiology AssociatesOverall official - principal investigator
- Jacksonville Center for Clinical ResearchOverall official - principal investigator
- Dartmouth UniversityOverall official - principal investigator
- Southern Illinois UniversityOverall official - principal investigator
- Colorado Prevention CenterCollaborator
- Department of Veteran AffairsOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.